Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Sahm

Showing results (1-10 of 449) with videos related to

Pageof 45
Sort By:
Neuro-Oncology|July 13, 2024
The morphology strikes backFelix Sahm
Neuro-Oncology|October 17, 2017
ID(H)entifying checkpoint inhibitor candidates among diffuse gliomaFelix Sahm, Antje Wick
Acta Neuropathologica|February 10, 2024
Reply: pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusionRamin Rahmanzade, Felix Sahm
Neuro-Oncology|October 2, 2018
TERT, the target?Felix Sahm, Michel Kalamarides
Brain Pathology (Zurich, Switzerland)|February 25, 2022
Introduction to the mini-symposium "molecular neuropathology of meningioma"Felix Sahm, Christian Mawrin
Seminars in Neurology|March 17, 2018
Practical Implications of the Updated WHO Classification of Brain TumorsMaria Martinez-Lage, Felix Sahm
Acta Neuropathologica|November 10, 2014
Farewell to oligoastrocytoma: response to lettersFelix Sahm, Andreas von Deimling
Neuro-Oncology|November 2, 2021
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncologyDrew Pratt, Felix Sahm, Kenneth Aldape
Current Opinion in Oncology|September 5, 2020
Molecular alterations in meningioma: prognostic and therapeutic perspectivesCristina Birzu, Matthieu Peyre, Felix Sahm
Oncotarget|September 26, 2012
Mutation specific antibodies: tool or dinosaur?Andreas von Deimling, Felix Sahm, David Capper
Pageof 45

Showing results (1-10 of 449) with videos related to

Sort By:
Pageof 45
Neuro-Oncology|July 13, 2024
The morphology strikes backFelix Sahm
Neuro-Oncology|October 17, 2017
ID(H)entifying checkpoint inhibitor candidates among diffuse gliomaFelix Sahm, Antje Wick
Acta Neuropathologica|February 10, 2024
Reply: pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusionRamin Rahmanzade, Felix Sahm
Neuro-Oncology|October 2, 2018
TERT, the target?Felix Sahm, Michel Kalamarides
Brain Pathology (Zurich, Switzerland)|February 25, 2022
Introduction to the mini-symposium "molecular neuropathology of meningioma"Felix Sahm, Christian Mawrin
Seminars in Neurology|March 17, 2018
Practical Implications of the Updated WHO Classification of Brain TumorsMaria Martinez-Lage, Felix Sahm
Acta Neuropathologica|November 10, 2014
Farewell to oligoastrocytoma: response to lettersFelix Sahm, Andreas von Deimling
Neuro-Oncology|November 2, 2021
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncologyDrew Pratt, Felix Sahm, Kenneth Aldape
Current Opinion in Oncology|September 5, 2020
Molecular alterations in meningioma: prognostic and therapeutic perspectivesCristina Birzu, Matthieu Peyre, Felix Sahm
Oncotarget|September 26, 2012
Mutation specific antibodies: tool or dinosaur?Andreas von Deimling, Felix Sahm, David Capper
Pageof 45